CTNM vs MS · $429.6M cap vs P/E 20, rev $41.93B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus Morgan Stanley (MS) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported MS revenue for 2026-06-30 was $41.93B. Net income was $11.15B. MS currently screens at market cap $344.27B and trailing P/E 19.8.
CTNM currently screens at market cap $429.6M. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Not investment advice. Open the CTNM and MS stock pages for the full models.
Not investment advice.